Literature DB >> 2580130

Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets.

K Landmark.   

Abstract

Sixteen nonhospitalized men, average age 41.3 years with essential hypertension (WHO I-II) were given nifedipine slow-release tablets of 20 mg twice daily for 48 weeks. Both supine and standing blood pressure values were significantly reduced, but heart rate was not significantly changed by the drug. A significant decrease in serum sodium and potassium was found. A slight increase in serum magnesium throughout the study became statistically significant at 48 weeks (p less than 0.05). It is suggested that a possible diuretic activity, and the increase in magnesium, may add to the direct nifedipine-induced blood pressure reduction. Serum creatinine increased significantly after 24 and 48 weeks of nifedipine administration; serum urea, cholesterol, triglycerides, uric acid, and blood glucose remained essentially unchanged. Most of the patients had low plasma renin activity (PRA) in the control period, and nifedipine significantly increased PRA. Body weight was kept constant. Side effects were few and of no clinical significance. The slow-release preparation of nifedipine seems to be a potent and effective drug in treating essential hypertension of a mild to moderate degree.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580130     DOI: 10.1097/00005344-198501000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Drug treatment in hypertension--metabolic side effects of drugs.

Authors:  P Little; A Trafford; G Girling; A Hasler; A Craven
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.

Authors:  V Challenor; D G Waller; B S Gruchy; A G Renwick; C F George; E T McMurdo; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 4.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 5.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Dose adjustment of nifedipine in hypertensive patients.

Authors:  N Bacracheva; P Thuermann; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group.

Authors: 
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.